The Journal of Allergy and Clinical Immunology
Volume 120, Issue 2 , Pages 273-277, August 2007

The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challenges

From the Division of Allergy, Asthma, and Immunology, Scripps Clinic

Received 9 February 2007; received in revised form 20 March 2007; accepted 22 March 2007. published online 04 May 2007.

San Diego, Calif

Background

Historical aspirin- or nonsteroidal anti-inflammatory drug (NSAID)–induced reactions might provide predictive information about the severity of reactions in patients with aspirin-exacerbated respiratory disease (AERD) undergoing oral aspirin challenge (OAC).

Objective

We sought to assess the relationship between historical aspirin- or NSAID-induced bronchial reactions and the severity of bronchial reactions during OAC in patients with AERD.

Methods

Data regarding the provoking doses, treatments, and treatment settings of historical aspirin/NSAID-induced reactions were recorded, analyzed, and compared with the provoking doses, maintenance regimens, and observed decreases in FEV1 that occurred during OAC in 210 consecutive patients referred with suspected AERD.

Results

Of 147 patients who reported seeking acute medical care for their historical aspirin/NSAID-induced asthma attacks, 101 (69%) were treated in an emergency department and released, and 46 (31%) required hospitalization. During OAC in these 147 subjects, 23 (16%) had a 20% to 29% decrease and 14 (10%) had a 30% or greater decrease in FEV1 values from baseline. Of the 46 patients previously hospitalized for aspirin/NSAID-induced asthma attacks, 9 (20%) had a 20% to 29% decrease and 6 (13%) had a 30% or greater decrease in FEV1 during OAC. By contrast, of the 63 patients who treated their prior aspirin/NSAID-induced reactions at home, 5 (8%) had a 20% to 29% decrease and 5 (8%) had a 30% or greater decrease in FEV1 during OAC (P = not significant for both).

Conclusion

The severity of the historical aspirin/NSAID-induced asthma attack was not predictive of asthma severity during OAC.

Clinical implications

These data provide further reassurance regarding the safety of outpatient aspirin desensitization.

Key words: Aspirin, nonsteroidal anti-inflammatory drugs, leukotrienes, leukotriene modifier drugs, asthma, aspirin-exacerbated respiratory disease, aspirin challenge, aspirin desensitization, nasal polyposis, chronic rhinosinusitis

Abbreviations used: AERD, Aspirin-exacerbated respiratory disease, ED, Emergency department, ICU, Intensive care unit, LTMD, Leukotriene modifier drug, NSAID, Nonsteroidal anti-inflammatory drug, OAC, Oral aspirin challenge

 

 Presented at the AAAAI Annual Meeting; February 25th, 2007; San Diego, Calif.Disclosure of potential conflict of interest: A. N. Williams is employed by Scripps Clinic. R. A. Simon is employed by Scripps Clinic and is on the speakers' bureau for Merck, Critical Therapeutics, GlaxoSmithKline, Schering, Novartis, Pfizer, and Sanofi-Aventis. K. M. Woessner is employed by Scripps Clinic and is on the speakers' bureau for Merck, GlaxoSmithKline, and Critical Therapeutics. D. D. Stevenson has consulting arrangements with Portola Pharmaceuticals; has received support from a Skaggs Institutional grant; is employed by Scripps Clinic and the Scripps Research Institute; is on the speakers' bureau for Merck and Critical Therapeutics; and has served as an expert witness for the defense in litigation.

PII: S0091-6749(07)00621-5

doi:10.1016/j.jaci.2007.03.020

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 2 , Pages 273-277, August 2007